The global market for endoscopic retrograde cholangiopancreatography (ERCP) devices is set to experience significant growth over the next decade, with estimates predicting sales to increase from USD 1 ...
Johnson & Johnson's Tremfya shows promising results in Phase 3 GRAVITI study for Crohn's disease, achieving significant clinical remission and endoscopic response at 48 weeks.